What’s Propelling Alpine Immune Sciences Inc (NASDAQ:ALPN) After Higher Shorts Reported?

September 14, 2018 - By Robert Crowder

The stock of Alpine Immune Sciences Inc (NASDAQ:ALPN) registered an increase of 1.8% in short interest. ALPN’s total short interest was 50,900 shares in September as published by FINRA. Its up 1.8% from 50,000 shares, reported previously. With 25,100 shares average volume, it will take short sellers 2 days to cover their ALPN’s short positions.

The stock increased 0.80% or $0.05 during the last trading session, reaching $6.29. About 67 shares traded. Alpine Immune Sciences, Inc. (NASDAQ:ALPN) has declined 35.10% since September 14, 2017 and is downtrending. It has underperformed by 50.72% the S&P500.

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. The company has market cap of $87.12 million. The Company’s lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. It currently has negative earnings. The firm has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein immunotherapies targeting the immune synapse to treat cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: